Press Releases

Date Title and Summary
Toggle Summary Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR in Treatment of Prader-Willi Syndrome
Protection of Associated Claims into 2035 REDWOOD CITY, Calif. , Sept. 13, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the issuance of a new patent
Toggle Summary Soleno Therapeutics Announces CFO Transition
David O’Toole to Depart Company ; Interim CFO Appointed and Search for New CFO Initiated REDWOOD CITY, Calif. , Sept. 05, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,
Toggle Summary Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results
Completed Successful FDA Meeting for DCCR in Prader-Willi Syndrome Preparing to begin Phase III program by the end of the year Monetized Non-Strategic Assets Through Sale of NeoForce, Inc. Subsidiary REDWOOD CITY, Calif. , Aug. 11, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc.
Toggle Summary Soleno Therapeutics Announces Sale of Non-Strategic Assets to Flexicare, Inc.
REDWOOD CITY, Calif. , July 24, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the sale of one of its non-strategic subsidiaries, NeoForce, Inc.
Toggle Summary Soleno Therapeutics Announces Successful Completion of FDA Meeting for DCCR in Prader-Willi Syndrome
Positive guidance received on key elements of Phase III program Company expects to initiate pivotal Phase III clinical trial by year-end 2017 DCCR has orphan designation for the treatment of PWS in the US REDWOOD CITY, Calif. , July 05, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc.
Toggle Summary Capnia Provides Corporate Update and Reports First Quarter 2017 Financial Results
Completed merger with Essentialis, Inc. and concurrent financing of $10 million New company name, Soleno Therapeutics, Inc. , to reflect new strategic focus on rare disease therapeutics; stock to trade under NASDAQ ticker symbol “SLNO” Scientific advice being obtained from the U.S.
Toggle Summary Capnia Reports Fourth Quarter and Full Year 2016 Financial Results
REDWOOD CITY, Calif. , March 15, 2017 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), focused on the development and commercialization of novel therapeutics for the treatment of rare diseases, today announced financial results for the fourth quarter and twelve months ended December 31, 2016 .
Toggle Summary Capnia Completes Merger with Essentialis Creating Rare Disease Therapeutics Company
Lead Clinical Asset Entering Phase II/III Development in 2017 for the  Treatment of Prader-Willi Syndrome Raises $10 Million in Concurrent Financing; Cash Runway Through Key Milestones REDWOOD CITY, Calif. , March 08, 2017 (GLOBE NEWSWIRE) -- Capnia, Inc.
Toggle Summary Capnia to Present at the 19th Annual BIO CEO & Investor Conference
REDWOOD CITY, Calif. , Feb. 07, 2017 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced that Anish Bhatnagar , M.D., Chief Executive
Toggle Summary Capnia and Essentialis Announce Merger to Create Rare Disease Therapeutics Company
Combined Company to Focus on Advancing Novel, Late-Stage Asset for the Treatment of Prader-Willi Syndrome, a Devastating, Orphan Disease  Enrollment in a Phase II/III Clinical Trial Expected to Begin in Second Half of 2017 $8 Million Concurrent Financing; Sufficient to Fund Development Plan Through
Print Page RSS Feeds Email Alerts IR Contacts